2017
DOI: 10.1182/bloodadvances.2017007930
|View full text |Cite
|
Sign up to set email alerts
|

The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study

Abstract: Key Points Prior malignancy negatively impacts survival in patients with MM and >1 prior malignancy reduces survival even further. A prior malignancy diagnosis increases the risk of developing a second malignancy in patients with MM.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
7
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 44 publications
(54 reference statements)
0
7
0
Order By: Relevance
“…In our study, the median time to development of AML/MDS was 3.8 years. During the majority of the study period, survival in multiple myeloma patients in Sweden was poor 42,52,53 . With significantly improved overall survival in multiple myeloma patients observed over the past decade, 5 future population‐based studies with multiple myeloma patients exposed to melphalan chemotherapy in the era of modern myeloma treatment will be important to better define long‐term risks.…”
Section: Discussionmentioning
confidence: 99%
“…In our study, the median time to development of AML/MDS was 3.8 years. During the majority of the study period, survival in multiple myeloma patients in Sweden was poor 42,52,53 . With significantly improved overall survival in multiple myeloma patients observed over the past decade, 5 future population‐based studies with multiple myeloma patients exposed to melphalan chemotherapy in the era of modern myeloma treatment will be important to better define long‐term risks.…”
Section: Discussionmentioning
confidence: 99%
“…To further build upon potential etiologies of SPM development, we did not observe an association between PMDs and SPM incidence, as opposed to the results from a Swedish population-based study among 19,097 MM patients diagnosed during 1973 and 2010 [ 7 ]. Explanations for these opposing results may lie in the type of regression analysis applied or the in- and exclusion criteria applied for synchronous malignancies, benign, borderline, and in situ malignancies, and basal-cell carcinomas.…”
mentioning
confidence: 57%
“…However, there is also a concurrrent increase in the incidence of subsequent primary malignancies (SPMs) [ 1 3 ]. Risk factors associated with SPMs in MM encompass treatment with alkylating agents or immunomodulatory drugs (IMiDs) [ 1 , 4 6 ], environmental exposures, genetic susceptibility to cancer, or combinations of these risk factors [ 7 , 8 ]. As MM survivorship is expected to increase, it is vital for clinicians to know how these risk factors influence SPM development in MM patients.…”
mentioning
confidence: 99%
“…Recent studies showed that MM patients had a higher risk of developing second malignancy than the general population [ 8 , 9 ]. Mailankody et al showed that MM patients had an 11-fold increased risk of developing acute myeloid leukemia and myelodysplastic syndromes and a twofold increased risk of developing nonmelanoma skin cancer [ 8 ].…”
Section: Discussionmentioning
confidence: 99%